ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center

Los Angeles, July 24, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA. Dana-Farber Cancer Institute is a world-renowned research and treatment center for cancer and other life-threatening diseases based in Boston, Massachusetts, a principal teaching affiliate of Harvard Medical School.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...